Wohl discusses START in WRAL story

David Wohl, MD, site leader of the UNC AIDS Clinical Trials Unit at Chapel Hill, was featured on WRAL explaining how the global interventional study Strategic Timing of Anti-Retroviral Treatment (START) definitively proves that patients found living with HIV should start antiretroviral therapy as early as possible to maintain their health.

Wohl says the trial should end the debate regarding the timing of HIV therapy that has raged since the first HIV medications became available and could lead the World Health Organization to change its recommended treatment guidelines. At UNC, 16 patients were enrolled it the trial.

Read and watch the story.